Nuclea has developed an extensive biorepository and database of associated clinical data. Utilizing the biorepository and database, Nuclea has the capability of selecting and analyzing genetic information associated with the occurrence or stage of disease, as well as the likelihood of recurrence and responsiveness to therapy of disease. Nuclea has the ability to develop tests, which can identify gene or protein expression profiles characteristic of specific diseases ("gene signatures") based on patient biological specimens. Nuclea has identified numerous gene signatures to date, and is discovering more on an ongoing basis. Nuclea develops highly accurate, fully-validated assays based on these gene signatures. These assays provide oncology clinicians with a powerful tool for refining and personalizing the treatment of cancer patients by allowing them to determine the likelihood of recurrence of the cancer and/or its response to a specific therapeutic. The company's current inventory includes fully validated IHC assays based on its proprietary gene signatures for colon and lung cancer.